Parkinson progression reduced by mild hyperbaric oxygen therapy

Mild or lower pressure hyperbaric oxygen therapy (aka m-HBOT) was able to demonstrate a marked reduction in Parkinson’s Disease (PD) symptoms in just 11 weeks!

PD is a common progressive neurodegenerative disease, of which the main neuropathological hallmark is dopaminergic neuronal loss (degeneration or loss of dopamine-producing neuronal cells). When dopamine-producing neurons die, motor functioning is affected and symptoms such as tremors, slowness, stiffness, and balance problems occur.

In this 11 week study, m-HBOT at 1.3 ATA (3 hours per day, 3 times per week) was able to protect the dopaminergic neurons from further loss and degeneration. More importantly, researchers observed positive effects in motor function <view study>

Hyperbaric oxygen therapy increases norepinephrine levels for the treatment of Parkinson’s Disease

Tissue concentrations of norepinephrine (NE) are markedly decreased in various regions of the brain in Parkinson patients. Not only is NE involved in cognitive operations, “freezing” of gait, tremor, dyskinesia, REM sleep regulation, and other aspects of brain function, but evidence also suggest its role in the neurodegenerative process itself. This study discusses the ability of hyperbaric oxygen therapy to help increase NE levels in the brain; thereby, helping to restore motor deficits in Parkinson’s disease patients <view study>